JP2005529874A - 乾燥粉末組成物 - Google Patents
乾燥粉末組成物 Download PDFInfo
- Publication number
- JP2005529874A JP2005529874A JP2003585696A JP2003585696A JP2005529874A JP 2005529874 A JP2005529874 A JP 2005529874A JP 2003585696 A JP2003585696 A JP 2003585696A JP 2003585696 A JP2003585696 A JP 2003585696A JP 2005529874 A JP2005529874 A JP 2005529874A
- Authority
- JP
- Japan
- Prior art keywords
- dry powder
- composition according
- pharmaceutical composition
- pack
- inhalation device
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000843 powder Substances 0.000 title claims abstract description 43
- 239000000203 mixture Substances 0.000 title claims description 73
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 30
- 208000023504 respiratory system disease Diseases 0.000 claims abstract description 9
- 150000001720 carbohydrates Chemical class 0.000 claims description 38
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 33
- 239000002245 particle Substances 0.000 claims description 24
- GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 18
- 229960000289 fluticasone propionate Drugs 0.000 claims description 16
- WMWTYOKRWGGJOA-CENSZEJFSA-N fluticasone propionate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O WMWTYOKRWGGJOA-CENSZEJFSA-N 0.000 claims description 16
- 239000003814 drug Substances 0.000 claims description 14
- 238000003860 storage Methods 0.000 claims description 11
- 229960004017 salmeterol Drugs 0.000 claims description 10
- 239000002775 capsule Substances 0.000 claims description 9
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 8
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 8
- 239000008101 lactose Substances 0.000 claims description 8
- 230000000694 effects Effects 0.000 claims description 7
- 150000003839 salts Chemical class 0.000 claims description 7
- 229940079593 drug Drugs 0.000 claims description 6
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 5
- 229930195725 Mannitol Natural products 0.000 claims description 5
- WOTQVEKSRLZRSX-HYSGBLIFSA-N [(2r,3r,4s,5r,6s)-4,5,6-triacetyloxy-3-[(2s,3r,4s,5r,6r)-3,4,5-triacetyloxy-6-(acetyloxymethyl)oxan-2-yl]oxyoxan-2-yl]methyl acetate Chemical compound CC(=O)OC[C@H]1O[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@@H](OC(C)=O)[C@@H]1O[C@H]1[C@H](OC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@@H](COC(C)=O)O1 WOTQVEKSRLZRSX-HYSGBLIFSA-N 0.000 claims description 5
- WOTQVEKSRLZRSX-UHFFFAOYSA-N beta-D-cellobioside octaacetate Natural products CC(=O)OCC1OC(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(COC(C)=O)O1 WOTQVEKSRLZRSX-UHFFFAOYSA-N 0.000 claims description 5
- 239000000594 mannitol Substances 0.000 claims description 5
- 235000010355 mannitol Nutrition 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- SJJCQDRGABAVBB-UHFFFAOYSA-N 1-hydroxy-2-naphthoic acid Chemical compound C1=CC=CC2=C(O)C(C(=O)O)=CC=C21 SJJCQDRGABAVBB-UHFFFAOYSA-N 0.000 claims description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 4
- 229930006000 Sucrose Natural products 0.000 claims description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 4
- 238000002664 inhalation therapy Methods 0.000 claims description 4
- 239000005720 sucrose Substances 0.000 claims description 4
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 3
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims description 3
- 229930091371 Fructose Natural products 0.000 claims description 3
- 239000005715 Fructose Substances 0.000 claims description 3
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 3
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims description 3
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 3
- WOTQVEKSRLZRSX-JRFIZLOQSA-N [(2r,3r,4s,5r,6r)-4,5,6-triacetyloxy-3-[(2s,3r,4s,5s,6r)-3,4,5-triacetyloxy-6-(acetyloxymethyl)oxan-2-yl]oxyoxan-2-yl]methyl acetate Chemical group CC(=O)OC[C@H]1O[C@H](OC(C)=O)[C@H](OC(C)=O)[C@@H](OC(C)=O)[C@@H]1O[C@H]1[C@H](OC(C)=O)[C@@H](OC(C)=O)[C@@H](OC(C)=O)[C@@H](COC(C)=O)O1 WOTQVEKSRLZRSX-JRFIZLOQSA-N 0.000 claims description 3
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 3
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 claims description 3
- 125000004432 carbon atom Chemical group C* 0.000 claims description 3
- 150000002016 disaccharides Chemical class 0.000 claims description 3
- 239000008103 glucose Substances 0.000 claims description 3
- 150000002772 monosaccharides Chemical class 0.000 claims description 3
- GUBGYTABKSRVRQ-CUHNMECISA-N D-Cellobiose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-CUHNMECISA-N 0.000 claims description 2
- ZIJKGAXBCRWEOL-SAXBRCJISA-N Sucrose octaacetate Chemical compound CC(=O)O[C@H]1[C@H](OC(C)=O)[C@@H](COC(=O)C)O[C@@]1(COC(C)=O)O[C@@H]1[C@H](OC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@@H](COC(C)=O)O1 ZIJKGAXBCRWEOL-SAXBRCJISA-N 0.000 claims description 2
- 239000001083 [(2R,3R,4S,5R)-1,2,4,5-tetraacetyloxy-6-oxohexan-3-yl] acetate Substances 0.000 claims description 2
- 239000001344 [(2S,3S,4R,5R)-4-acetyloxy-2,5-bis(acetyloxymethyl)-2-[(2R,3R,4S,5R,6R)-3,4,5-triacetyloxy-6-(acetyloxymethyl)oxan-2-yl]oxyoxolan-3-yl] acetate Substances 0.000 claims description 2
- NJVBTKVPPOFGAT-BRSBDYLESA-N [(2r,3r,4r,5r)-2,3,4,5,6-pentaacetyloxyhexyl] acetate Chemical compound CC(=O)OC[C@@H](OC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H](OC(C)=O)COC(C)=O NJVBTKVPPOFGAT-BRSBDYLESA-N 0.000 claims description 2
- UAOKXEHOENRFMP-ZJIFWQFVSA-N [(2r,3r,4s,5r)-2,3,4,5-tetraacetyloxy-6-oxohexyl] acetate Chemical compound CC(=O)OC[C@@H](OC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@@H](OC(C)=O)C=O UAOKXEHOENRFMP-ZJIFWQFVSA-N 0.000 claims description 2
- HWDSLHMSWAHPBA-UHFFFAOYSA-N [3,4,5-triacetyloxy-6-[3,4,5-triacetyloxy-6-(acetyloxymethyl)oxan-2-yl]oxyoxan-2-yl]methyl acetate Chemical compound CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(COC(=O)C)OC1OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(COC(C)=O)O1 HWDSLHMSWAHPBA-UHFFFAOYSA-N 0.000 claims description 2
- 230000002411 adverse Effects 0.000 claims description 2
- 238000004891 communication Methods 0.000 claims description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 2
- 150000002430 hydrocarbons Chemical group 0.000 claims description 2
- 230000002209 hydrophobic effect Effects 0.000 claims description 2
- 229940013883 sucrose octaacetate Drugs 0.000 claims description 2
- 238000004804 winding Methods 0.000 claims description 2
- 230000037406 food intake Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 229940112141 dry powder inhaler Drugs 0.000 abstract description 7
- 239000002260 anti-inflammatory agent Substances 0.000 abstract description 3
- 229940124599 anti-inflammatory drug Drugs 0.000 abstract description 3
- 229940124630 bronchodilator Drugs 0.000 abstract description 3
- 230000003637 steroidlike Effects 0.000 abstract description 3
- 235000014633 carbohydrates Nutrition 0.000 description 25
- 239000013543 active substance Substances 0.000 description 16
- 229960005018 salmeterol xinafoate Drugs 0.000 description 8
- 239000000126 substance Substances 0.000 description 7
- 229960001375 lactose Drugs 0.000 description 6
- 238000002156 mixing Methods 0.000 description 5
- 208000006673 asthma Diseases 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 239000010419 fine particle Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 2
- 206010014561 Emphysema Diseases 0.000 description 2
- 238000012387 aerosolization Methods 0.000 description 2
- 206010006451 bronchitis Diseases 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- 206010039083 rhinitis Diseases 0.000 description 2
- 238000004808 supercritical fluid chromatography Methods 0.000 description 2
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229960004977 anhydrous lactose Drugs 0.000 description 1
- 229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- 125000000837 carbohydrate group Chemical group 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 238000000975 co-precipitation Methods 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000007373 indentation Methods 0.000 description 1
- 229960001021 lactose monohydrate Drugs 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 238000004513 sizing Methods 0.000 description 1
- 239000007962 solid dispersion Substances 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006068 taste-masking agent Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pulmonology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Otolaryngology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0208609.8A GB0208609D0 (en) | 2002-04-13 | 2002-04-13 | Compositions |
| PCT/GB2003/001595 WO2003088944A1 (en) | 2002-04-13 | 2003-04-10 | Dry powder inhalant composition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005529874A true JP2005529874A (ja) | 2005-10-06 |
| JP2005529874A5 JP2005529874A5 (https=) | 2006-06-01 |
Family
ID=9934856
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003585696A Pending JP2005529874A (ja) | 2002-04-13 | 2003-04-10 | 乾燥粉末組成物 |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US20050232998A1 (https=) |
| EP (1) | EP1509199A1 (https=) |
| JP (1) | JP2005529874A (https=) |
| KR (1) | KR20040097348A (https=) |
| CN (1) | CN100362986C (https=) |
| AR (1) | AR039408A1 (https=) |
| AU (1) | AU2003224278A1 (https=) |
| BR (1) | BR0309115A (https=) |
| CA (1) | CA2482249A1 (https=) |
| GB (1) | GB0208609D0 (https=) |
| IL (1) | IL164421A0 (https=) |
| IS (1) | IS7501A (https=) |
| MX (1) | MXPA04010082A (https=) |
| NO (1) | NO20044496L (https=) |
| PL (1) | PL373293A1 (https=) |
| RU (1) | RU2004130438A (https=) |
| TW (1) | TW200407174A (https=) |
| WO (1) | WO2003088944A1 (https=) |
| ZA (1) | ZA200408247B (https=) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009513531A (ja) * | 2003-07-11 | 2009-04-02 | グラクソ グループ リミテッド | 糖エステルを含む吸入可能医薬製剤 |
| JP2014522880A (ja) * | 2011-08-08 | 2014-09-08 | プロソニックス リミテッド | 製剤組成物 |
| JP2016519123A (ja) * | 2013-04-29 | 2016-06-30 | サノフィ・ソシエテ・アノニム | 吸入可能な医薬組成物およびそれらを収容した吸入器デバイス |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003024396A2 (en) | 2001-09-17 | 2003-03-27 | Glaxo Group Limited | Dry powder medicament formulations |
| WO2006086270A1 (en) | 2005-02-10 | 2006-08-17 | Glaxo Group Limited | Processes for making lactose utilizing pre-classification techniques and pharmaceutical formulations formed therefrom |
| GB0605723D0 (en) | 2006-03-23 | 2006-05-03 | 3M Innovative Properties Co | Powder filling processes |
| GB0714134D0 (en) * | 2007-07-19 | 2007-08-29 | Norton Healthcare Ltd | Dry-powder medicament |
| WO2009031011A2 (en) * | 2007-09-05 | 2009-03-12 | Pfizer Limited | Xinafoate salt of n4-(2, 2-difluoro-4h-benz0 [1,4] 0xazin-3-one) -6-yl] -5-fluoro-n2- [3- (methylaminocar bonylmethyleneoxy) phenyl] 2, 4-pyrimidinediamine |
| TR201007251A2 (tr) * | 2010-09-01 | 2012-03-21 | Bi̇lgi̇ç Mahmut | Kalsiyum kanal blokörü formülasyonu. |
| TR201007250A2 (tr) * | 2010-09-01 | 2012-03-21 | Bi̇lgi̇ç Mahmut | Selobioz içeren formülasyon. |
| JOP20120023B1 (ar) | 2011-02-04 | 2022-03-14 | Novartis Ag | صياغات مساحيق جافة من جسيمات تحتوي على واحد أو اثنين من المواد الفعالة لعلاج امراض ممرات الهواء الانسدادية او الالتهابية |
| EP2819645A2 (en) * | 2012-02-28 | 2015-01-07 | Iceutica Holdings Inc. Bvi | Inhalable pharmaceutical compositions |
| US8765725B2 (en) | 2012-05-08 | 2014-07-01 | Aciex Therapeutics, Inc. | Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof |
| AU2013259872B2 (en) | 2012-05-08 | 2018-06-28 | Nicox Ophthalmics, Inc. | Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof |
| EP2874928B1 (en) | 2012-07-19 | 2016-06-15 | Adamis Pharmaceuticals Corporation | Powder feeding apparatus |
| US9815865B2 (en) | 2013-01-07 | 2017-11-14 | Nicox Ophthalmics, Inc. | Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof |
| CN104644618A (zh) * | 2013-11-19 | 2015-05-27 | 上海医药工业研究院 | 一种干粉吸入剂及其制备方法 |
| ES2942297T3 (es) * | 2014-07-31 | 2023-05-31 | Vectura Inc | Formulaciones de polvo seco para inhalación |
| WO2016052897A1 (en) * | 2014-09-30 | 2016-04-07 | Hanmi Pharm. Co., Ltd. | Dry powder for inhalation formulation having improved stability of combined active ingredients |
| KR20160117069A (ko) * | 2015-03-31 | 2016-10-10 | 한미약품 주식회사 | 복합 활성성분의 안정성이 개선된 흡입용 캡슐제 |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH03167120A (ja) * | 1989-09-08 | 1991-07-19 | Glaxo Group Ltd | 呼吸疾患治療薬 |
| JPH04220266A (ja) * | 1990-03-02 | 1992-08-11 | Glaxo Group Ltd | 吸入装置 |
| WO2001003673A1 (en) * | 1999-07-12 | 2001-01-18 | Quadrant Healthcare (Uk) Limited | Dry powder compositions |
| JP2001527087A (ja) * | 1997-12-23 | 2001-12-25 | クアドラント ホールディングス ケンブリッジ リミテッド | 固体輸送系において有用な炭水化物 |
| WO2002015876A2 (en) * | 2000-08-21 | 2002-02-28 | Quadrant Healthcare (Uk) Limited | Amorphous carrier materials for drug delivery |
| JP2002510316A (ja) * | 1997-07-03 | 2002-04-02 | クアドラント ホールディングス ケンブリッジ リミテッド | 修飾グリコシド、これを含む組成物およびその使用方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR8007911A (pt) * | 1979-12-06 | 1981-06-16 | Glaxo Group Ltd | Inalador aperfeicoado |
| SE448277B (sv) * | 1985-04-12 | 1987-02-09 | Draco Ab | Indikeringsanordning vid en doseringsanordning for lekemedel |
| DE3682457D1 (de) * | 1985-07-30 | 1991-12-19 | Glaxo Group Ltd | Geraet zur verabreichung von medikamenten an patienten. |
| US5202309A (en) * | 1989-06-30 | 1993-04-13 | Merck & Co., Inc. | Antibiotic cyclopeptide fermentation product |
| SE9302777D0 (sv) * | 1993-08-27 | 1993-08-27 | Astra Ab | Process for conditioning substances |
| SE9700135D0 (sv) * | 1997-01-20 | 1997-01-20 | Astra Ab | New formulation |
| UA73965C2 (en) * | 1999-12-08 | 2005-10-17 | Theravance Inc | b2 ADRENERGIC RECEPTOR ANTAGONISTS |
| AU3664102A (en) * | 2000-12-01 | 2002-06-11 | Battelle Memorial Institute | Method for stabilizing biomolecules in liquid formulations |
| NZ528640A (en) * | 2001-03-30 | 2004-06-25 | Jagotec Ag | Medical aerosol formulations |
| EP1507754A1 (en) * | 2002-05-28 | 2005-02-23 | Theravance, Inc. | Alkoxy aryl beta-2 adrenergic receptor agonists |
-
2002
- 2002-04-13 GB GBGB0208609.8A patent/GB0208609D0/en not_active Ceased
-
2003
- 2003-04-10 CA CA002482249A patent/CA2482249A1/en not_active Abandoned
- 2003-04-10 RU RU2004130438/15A patent/RU2004130438A/ru not_active Application Discontinuation
- 2003-04-10 BR BR0309115-5A patent/BR0309115A/pt not_active IP Right Cessation
- 2003-04-10 KR KR10-2004-7016301A patent/KR20040097348A/ko not_active Withdrawn
- 2003-04-10 MX MXPA04010082A patent/MXPA04010082A/es unknown
- 2003-04-10 US US10/510,968 patent/US20050232998A1/en not_active Abandoned
- 2003-04-10 JP JP2003585696A patent/JP2005529874A/ja active Pending
- 2003-04-10 EP EP03720702A patent/EP1509199A1/en not_active Withdrawn
- 2003-04-10 PL PL03373293A patent/PL373293A1/xx unknown
- 2003-04-10 CN CNB038134608A patent/CN100362986C/zh not_active Expired - Fee Related
- 2003-04-10 WO PCT/GB2003/001595 patent/WO2003088944A1/en not_active Ceased
- 2003-04-10 AU AU2003224278A patent/AU2003224278A1/en not_active Abandoned
- 2003-04-11 TW TW092108404A patent/TW200407174A/zh unknown
- 2003-04-11 AR ARP030101279A patent/AR039408A1/es not_active Application Discontinuation
-
2004
- 2004-10-05 IL IL16442104A patent/IL164421A0/xx unknown
- 2004-10-11 IS IS7501A patent/IS7501A/is unknown
- 2004-10-12 ZA ZA200408247A patent/ZA200408247B/xx unknown
- 2004-10-21 NO NO20044496A patent/NO20044496L/no not_active Application Discontinuation
-
2007
- 2007-11-05 US US11/934,983 patent/US20080060645A1/en not_active Abandoned
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH03167120A (ja) * | 1989-09-08 | 1991-07-19 | Glaxo Group Ltd | 呼吸疾患治療薬 |
| JPH04220266A (ja) * | 1990-03-02 | 1992-08-11 | Glaxo Group Ltd | 吸入装置 |
| JP2002510316A (ja) * | 1997-07-03 | 2002-04-02 | クアドラント ホールディングス ケンブリッジ リミテッド | 修飾グリコシド、これを含む組成物およびその使用方法 |
| JP2001527087A (ja) * | 1997-12-23 | 2001-12-25 | クアドラント ホールディングス ケンブリッジ リミテッド | 固体輸送系において有用な炭水化物 |
| WO2001003673A1 (en) * | 1999-07-12 | 2001-01-18 | Quadrant Healthcare (Uk) Limited | Dry powder compositions |
| WO2002015876A2 (en) * | 2000-08-21 | 2002-02-28 | Quadrant Healthcare (Uk) Limited | Amorphous carrier materials for drug delivery |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009513531A (ja) * | 2003-07-11 | 2009-04-02 | グラクソ グループ リミテッド | 糖エステルを含む吸入可能医薬製剤 |
| JP2014522880A (ja) * | 2011-08-08 | 2014-09-08 | プロソニックス リミテッド | 製剤組成物 |
| US9220708B2 (en) | 2011-08-08 | 2015-12-29 | Prosonix Limited | Pharmaceutical compositions |
| JP2016519123A (ja) * | 2013-04-29 | 2016-06-30 | サノフィ・ソシエテ・アノニム | 吸入可能な医薬組成物およびそれらを収容した吸入器デバイス |
Also Published As
| Publication number | Publication date |
|---|---|
| GB0208609D0 (en) | 2002-05-22 |
| US20080060645A1 (en) | 2008-03-13 |
| AU2003224278A1 (en) | 2003-11-03 |
| NO20044496L (no) | 2004-11-15 |
| ZA200408247B (en) | 2006-03-29 |
| CN1658837A (zh) | 2005-08-24 |
| AR039408A1 (es) | 2005-02-16 |
| EP1509199A1 (en) | 2005-03-02 |
| RU2004130438A (ru) | 2005-06-10 |
| CA2482249A1 (en) | 2003-10-30 |
| US20050232998A1 (en) | 2005-10-20 |
| TW200407174A (en) | 2004-05-16 |
| MXPA04010082A (es) | 2004-12-13 |
| BR0309115A (pt) | 2005-02-01 |
| CN100362986C (zh) | 2008-01-23 |
| KR20040097348A (ko) | 2004-11-17 |
| PL373293A1 (en) | 2005-08-22 |
| WO2003088944A1 (en) | 2003-10-30 |
| IS7501A (is) | 2004-10-11 |
| IL164421A0 (en) | 2005-12-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20080060645A1 (en) | Dry Powder Inhalant Composition | |
| EP0818991B1 (en) | Controlled release insufflation carrier for medicaments comprising xanthan gum and locust bean gum | |
| ES2718455T3 (es) | Formulaciones terapéuticas sostenidas inhalables | |
| US9549936B2 (en) | Method for preparing dry powder for inhalation formulation comprising salmeterol xinafoate, fluticasone propionate and tiotropium bromide | |
| US7754242B2 (en) | Inhalable sustained therapeutic formulations | |
| AU2008325290B2 (en) | Dry powder formulations comprising ascorbic acid derivates | |
| CN105101955A (zh) | 至少包含两种通过喷雾干燥以增加制剂稳定性而得到的干粉的组合物 | |
| KR102462058B1 (ko) | 제제의 안정성을 증가시키기 위해 분무 건조에 의해 수득된 1종 이상의 건조 분말을 포함하는 조성물 | |
| JP2007509124A (ja) | ステアリン酸カルシウムを含む吸入療法用乾燥粉末組成物およびそのための医療デバイス | |
| JP2005530733A (ja) | 乾燥粉末組成物 | |
| US20050152847A1 (en) | Novel formulation | |
| MXPA06004984A (en) | Soft steroid compositions for use in dry powder inhalers |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060403 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20060403 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20091027 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20100323 |